NewAmsterdam Grants 71,800 Inducement Options at $24.16

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced on Oct. 2, 2026 that its board compensation committee approved inducement grants of 71,800 share options at a $24.16 strike and 17,745 restricted stock units to 7 non-executive new hires. The options carry an exercise price equal to the Oct. 1, 2026 closing market price on the Nasdaq Stock Market, which the company identified as the grant date. The company said the awards were material inducements to employment under its 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

Context — why a routine inducement filing matters for NAMS

The grant leans on a narrow Nasdaq exemption. Listing Rule 5635(c)(4) lets a company issue options or stock outside shareholder approval, but only to someone joining the firm, and only as an inducement to accept that offer. The company said these went to non-executive new hires, which places the grants inside the exemption rather than under a shareholder-approved equity plan.

The report gives no prior-period inducement grant for comparison. It also does not disclose the company's total shares outstanding, so the dilution from these awards cannot be expressed as a percentage of the float. The company did not disclose the aggregate grant-date fair value of the options, which would require an option-pricing model input the release omits.

The timing is what gives the filing weight. NewAmsterdam describes itself as a late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol. The company said it is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in multiple Phase 3 trials. Hiring into that phase of a development program is a cost decision, and equity is one way a clinical-stage issuer pays for it without drawing down cash.

The company also frames the opportunity set broadly. It said it is dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases, and that it is advancing therapies for patients for whom existing therapies are not sufficiently effective or well-tolerated. Those are the company's stated expectations, not established outcomes.

Data — what the numbers show

The option strike is the anchor figure. At $24.16 per share, the 71,800 options carry an aggregate exercise value of roughly $1.73 million, calculated from the figures the company disclosed. That is the cash employees would pay to convert the options into shares, not a cost to NewAmsterdam.

The vesting schedules are the second concrete set of numbers. The options vest over four years: 25% on the one-year anniversary of the applicable vesting commencement date, then the balance in 36 equal monthly installments. The restricted stock units vest over three years, one-third on each anniversary of the vesting commencement date. Both are conditioned on continued service.

Award	Units	Strike / Price	Vesting
Share options	71,800	$24.16	4 years, 25% at year one, then 36 monthly
Restricted stock units	17,745	n/a	3 years, one-third annually

The combined share count underlying both awards is 89,545. The report does not give a peer comparison, and it does not name a comparable grant from another issuer, so no sector benchmark can be drawn from the release itself.

Analysis — what it means for markets and the NAMS ticker

The first-order read is dilution, and the second-order read is hiring. Restricted stock units convert to shares as they vest with no cash payment, so the 17,745 units are the cleaner measure of eventual share issuance. The options only become shares if employees exercise, which requires the stock to be worth more than $24.16 at that point.

That strike sets an implicit reference level. Because the exercise price equals the Oct. 1, 2026 close, the awards were struck at the money on the grant date. Employees holding them have no built-in gain until NAMS trades above that level, which aligns the new hires with the share price rather than with a discounted entry.

The exposure sits with NAMS holders, not with a broad sector. Inducement grants at this scale do not move cardiovascular or biotech indices. What they do is add to the share count over a multi-year window, which matters most to investors already modeling per-share economics ahead of clinical data.

The counter-argument is that the dilution is small and the retention value is real. Seven hires is a narrow cohort, and equity is standard compensation for a clinical-stage issuer that would otherwise need cash. A skeptical holder would note the company gave no cash cost, no fair value, and no headcount context, so the filing cannot be sized against the balance sheet.

Positioning follows the clinical calendar rather than the grant. Holders of NAMS are effectively long an obicetrapib data path, and the inducement awards are a footnote to that. There is no flow signal in a filing of this size.

Outlook — what to watch next

The company gave no dates for its Phase 3 readouts in this release, so the near-term catalyst set is limited to what the report supports. The first thing to watch is whether NewAmsterdam files additional inducement grants, which would show continued hiring against the 2024 Inducement Plan.

The second is the share count. Any subsequent disclosure of total ordinary shares outstanding would let holders convert these 89,545 units into a dilution percentage, which this release does not provide.

The third is the $24.16 level itself. It is the only price the report names, and it is the strike on the option tranche. Trading below it leaves the options out of the money; trading above it puts the tranche in the money for the seven holders. None of this is a prediction, only the arithmetic the grant defines.

Frequently Asked Questions

What does an inducement grant under Nasdaq Rule 5635(c)(4) mean?

It means a company issued equity to a new employee without asking shareholders to vote on it. Nasdaq requires the grant to be a material inducement to that person accepting the job, which is why the awards go to new hires rather than existing staff. NewAmsterdam said all 7 recipients were non-executive new hires, keeping the grants inside the exemption.

How much dilution do 71,800 options and 17,745 RSUs create for NAMS holders?

That cannot be calculated from this release. The report does not state NewAmsterdam's total ordinary shares outstanding, so the 89,545 units underlying the two awards cannot be expressed as a percentage. What the report does give is the $24.16 option strike, which is the price employees must pay to convert options into shares.

Why is the option exercise price set at $24.16?

Because that was the closing market price of NewAmsterdam's ordinary shares on the Nasdaq Stock Market on Oct. 1, 2026, which the company identified as the grant date. Setting the strike at the grant-date close means the options were issued at the money, so holders see no gain until the shares trade above that level.

Bottom Line

NewAmsterdam's 89,545-unit inducement grant adds multi-year dilution tied to a $24.16 strike that now serves as the reference level for seven new hires.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.